Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 192-199

  Stojković, Tihomir ^a   Radonjić, Nevena V ^a   Velimirović, Milica ^a   Jevtić, Gordana ^a   Popović, Vera ^a   Doknić, Mirjana ^a   Petronijević, Nataša D ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Antioxidant enzymes; Glutathione; Phencyclidine; Risperidone; Schizophrenia

Indexed keywords

GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; LIPID PEROXIDE; PHENCYCLIDINE; RISPERIDONE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; SCHIZOPHRENIA; THALAMUS; UPREGULATION;

ANIMALS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; LIPID PEROXIDATION; MALE; PHENCYCLIDINE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, WISTAR; RISPERIDONE; SCHIZOPHRENIA;

EID: 84864521326     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.06.013     Document Type: Article

References (75)

1. Adams S.M., de Rivero Vaccari J.C., Corriveau R.A. Pronounced cell death in the absence of NMDA receptors in the developing somatosensory thalamus. J Neurosci 2004, 24:9441-9450.
2. Akyol O., Herken H., Uz E., Fadillioǧlu E., Unal S., Söǧüt S., et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:995-1005.
3. Altuntas I., Aksoy H., Coskun I., Cayköylü A., Akçay F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med 2000, 38:1277-1281.
4. Andersen J.D., Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of d-serine. Neuropsychopharmacology 2004, 29:1080-1090.
5. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 2003, 53:56-64.
6. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011, 35:878-893.
7. Behrens M.M., Ali S.S., Dao D.N., Lucero J., Shekhtman G., Quick K.L., et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 2007, 318:1645-1647.
8. du Bois T.M., Huang X.F., Deng C. Perinatal administration of PCP alters adult behaviour in female Sprague-Dawley rats. Behav Brain Res 2008, 188:416-419.
9. Brown K., Reid A., White T., Henderson T., Hukin S., Johnstone C., et al. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol Psychiatry 1998, 43:863-867.
10. Carlberg I., Mannervik B. Glutathione reductase. Methods Enzymol 1985, 113:484-490.
11. Che Y., Wang J.F., Shao L., Young T. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci 2010, 35:296-302.
12. Choi Y.K., Gardner M.P., Tarazi F.I. Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur Neuropsychopharmacol 2009, 19:77-84.
13. Cosgrove J., Newell T. Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 1991, 47:159-169.
14. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006, 26:365-384.
15. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209.
16. de Oliveira L., Spiazzi C.M., Bortolin T., Canever L., Petronilho F., Mina F.G., et al. Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1003-1008.
17. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000, 12:3721-3728.
18. Do K.Q., Cabungcal J.H., Frank A., Steullet P., Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009, 19:220-230.
19. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
20. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003, 69:393-399.
21. Fraguas D., Gonzalez-Pinto A., Micó J.A., Reig S., Parellada M., Martínez Cengotitabengoa M. Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. Schizophr Res 2012, 10.1016/j.schres.2012.01.040.
22. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011, 14:123-130.
23. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156:117-154.
24. Günzler W.A., Kremers H., Flohé L. An improved coupled test procedure for glutathione peroxidase (EC 1-11-1-9-) in blood. Z Klin Chem Klin Biochem 1974, 12:444-448.
25. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vöckler J., Dikranian K., et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999, 283:70-74.
26. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
27. Jones D.P. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008, 295:C849-C868.
28. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
29. Kim J.J., Lee S.J., Toh K.Y., Lee C.U., Lee C., Paik I.H. Identification of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia. Schizophr Res 2001, 52:127-135.
30. Köhr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res 2006, 326:439-446.
31. Kohr G., Eckardt S., Luddens H., Monyer H., Seeburg P.H. NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron 1994, 12:1031-1040.
32. Kropp S., Kern V., Lange K., Degner D., Hajak G., Kornhuber J., et al. Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci 2005, 17:227-231.
33. Lepping P., Delieu J., Mellor R., Williams J.H., Hudson P.R., Hunter-Lavin C. Antipsychotic medication and oxidative cell stress: a systematic review. J Clin Psychiatry 2011, 72:273-285.
34. Lewis D.A., Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 2002, 25:409-432.
35. Lipton S.A., Choi Y.B., Takahashi H., Zhang D., Li W., Godzik A., et al. Cysteine regulation of protein function - as exemplified by NMDA-receptor modulation. Trends Neurosci 2002, 25:474-480.
36. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
37. Lu S.C. Regulation of glutathione synthesis. Mol Aspects Med 2009, 30:42-59.
38. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998, 43:674-679.
39. Matsuzawa D., Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal 2011, 15:2057-2065.
40. Mićić D.V., Petronijević N.D., Vucetić S.S. Superoxide dismutase activity in the mongolian gerbil brain after acute poisoning with aluminum. J Alzheimers Dis 2003, 5:49-56.
41. Mićić D.V., Petronijević N.D. Acetylcholinesterase activity in the mongolian gerbil brain after acute poisoning with aluminum. J Alzheimers Dis 2000, 2:1-6.
42. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999, 33:523-533.
43. Petronijević N.D., Mićić D.V., Duričić B., Marinković D., Paunović V.R. Substrate kinetics of erythrocyte membrane Na, K-ATPase and lipid peroxides in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:431-440.
44. Pillai A., Parikh V., Terry A.V., Mahadik S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007, 41:372-386.
45. Radonjić N.V., Knežević I.D., Vilimanovich U., Kravić-Stevović T., Marina L.V., Nikolić T., et al. Decreased glutathione levels and altered antioxidant defense in animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Neuropharmacology 2010, 58:739-745.
46. Raffa M., Atig F., Mhalla A., Kerkeni A., Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011, 11:124.
47. Raffa M., Mechri A., Othman L.B., Fendri C., Gaha L., Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1178-1183.
48. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122.
49. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005, 10:434-449.
50. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996, 55:33-43.
51. Reddy R., Mahadik S.P., Mukherjee M., et al. Enzymes of the antioxidant system in chronic schizophrenic patients. Biol Psychiatry 1991, 30:409-412.
52. Rehncrona S., Smith D.S., Akesson B., Westerberg E., Siesjö B.K. Peroxidative changes in brain cortical fatty acids and phospholipids, as characterized during Fe2+- and ascorbic acid-stimulated lipid peroxidation in vitro. J Neurochem 1980, 34:1630-1638.
53. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996, 124:57-73.
54. Seelig G.F., Meister A. Glutathione biosynthesis; gamma-glutamylcysteine synthetase from rat kidney. Methods Enzymol 1985, 113:379-390.
55. Sircar R. Postnatal phencyclidine-induced deficit in adult water maze performance is associated with N-methyl-d-aspartate receptor upregulation. Int J Dev Neurosci 2003, 21:159-167.
56. Stefani M.R., Moghaddam B. Transient N-methyl-d-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 2005, 57:433-436.
57. Steullet P., Neijt H.C., Cuenod M., Do K.Q. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 2006, 137:807-819.
58. Sun M., Zigman S. An improved spectrophotometric assay for superoxide dismutase based on epinephrine autoxidation. Anal Biochem 1978, 90:81-89.
59. Terpstra M., Vaughan T.J., Ugurbil K., Lim K.O., Schulz S.C., Gruetter R. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. MAGMA 2005, 18:276-282.
60. Terry A.V., Gearhart D.A., Warner S., Hohnadel E.J., Middlemore M.L., Zhang G., et al. Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats. Neuroscience 2007, 150:413-424.
61. Tosic M., Ott J., Barral S., Bovet P., Deppen P., Gheorghita F., et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2006, 79:586-592.
62. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
63. Van O.J., Rutten B.P., Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 2008, 34:1066-1082.
64. Wang C., McInnis J., West J.B., Bao J., Anastasio N., Guidry J.A., et al. Blockade of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by M40403, a superoxide dismutase mimetic. J Pharmacol Exp Ther 2003, 304:266-271.
65. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J.L., Johnson K.M. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 2001, 107:535-550.
66. Whittaker V.P., Barker L.A. The subcellular fractionation of brain tissue with special reference to the preparation of synaptosomes and their component organelles. Methods Neuroch 1972, 2:1-52.
67. Wood S.J., Berger G.E., Wellard R.M., Proffitt T.M., McConchie M., et al. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis 2009, 33:354-357.
68. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 2006, 22:83-93.
69. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15:287-310.
70. Yao J.K., Reddy R., McElhinny L.G., et al. Effect of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998, 32:385-391.
71. Zhang X.Y., Zhou D.F., Shen Y.C., Zhang P.Y., Zhang W.F., Liang J., et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 2012, 62:1928-1934.
72. Zhang M., Zhao Z., He L., Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci 2010, 53:112-124.
73. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006, 81:291-300.
74. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J Clin Psychopharmacol 2003, 23:128-131.
75. Zhang X.Y., Zhou D.F., Su J.M., Zhang P.Y. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J Clin Psychopharmacol 2001, 21:85-88.